AM Biotech, a pioneering force in bio-pulsed exosome research, has been honored with the 21st National Innovation Award. This is a high commendation for AM Biotech’s long-standing dedication to research and innovation in the field of bio-pulsed exosomes.

AM Biotech’s groundbreaking “Cross-generational Bio-Pulse Exosome Application Platform”, which was awarded the National Innovation Award, can significantly reduce product development time and cost. Leveraging this platform, the company successfully launched Exo Giov in 2021, a cosmetic product harnessing the power of bio-pulsed exosomes for beauty and hair care. Additionally, AM Biotech is in the advanced stages of developing exosome-based treatments for a wide range of diseases, including menopause, ophthalmic disorders, otology, periodontitis, joint diseases, and chronic kidney disease.

Bio-Pulse Activation Technology

AM Biotech’s patented bio-pulse activation technology empowers the company to develop and produce high-quality bio-pulsed exosomes. Compared to conventional exosomes, AM Biotech’s exosomes exhibit significantly enhanced efficacy, with a 202% increase in protein content and a 188% increase in miRNA content. These enhancements make them highly effective in promoting cell repair and tissue regeneration.

Cross-generational Bio-Pulse Exosome Application Platform

This innovative platform is built upon AM Biotech’s patented bio-pulse activation technology and three other core technologies:

Bio-Pulse Activation Technology: Exosomes produced using this technology exhibit several to dozens of times greater efficacy in treating diseases, enhancing beauty, and promoting hair growth compared to conventional exosomes.
High-efficiency exosome production technology: Enables storage at room temperature.
Exosome Ultra-Purification Extraction Technology: Achieves a purity level of 99.99%.
Advanced Mass Production Process: Ensures consistent product quality.

AM Bio Tech’s “Patented Bio-Pulsed Technology Forum” held on December 15, 2024, successfully concluded. The event delved deep into the groundbreaking innovation behind Patented Bio-Pulsed Technology, shedding light on its mechanisms and providing compelling evidence of its effectiveness in skin rejuvenation and hair restoration.

The forum attracted a distinguished audience of medical aesthetics, beauty, and hair care professionals who were eager to learn more about this cutting-edge technology and its potential applications. Attendees gained valuable insights into the technology’s clinical efficacy, making it a compelling choice for their product offerings.

Dr. Huang Chi-Chia, President of the Chinese Society of Cosmetic Surgery and Anti-aging Medicine, emphasized the growing significance of Patented Bio-Pulsed Technology in the medical aesthetics industry. “This technology is not only innovative in its scientific underpinnings but also delivers tangible results in clinical practice,” he remarked. “It offers a comprehensive solution for both beauty and hair restoration.”

Scientific Validation and Clinical Success

Dr. Richard Hsieh, Chairman of AM Bio Tech highlighted AM Bio Tech’s unique patented bio-pulsed technology, which produces exosome medical raw materials with a purity of up to 99.99%. This exceptional purity translates into significantly enhanced collagen, elastin, and fibroblast production, as well as hair follicle stimulation compared to conventional exosomes. Moreover, AM Bio Tech’s technology allows for room temperature storage, expanding the applications of exosome-based hair care and skincare products.

Independent testing conducted by SGS further solidified the technology’s efficacy. The results revealed that 100% of participants experienced increased collagen levels and more even skin tone, while 97% reported increased hair density and stronger hair roots. These remarkable outcomes are attributed to AM Bio Tech’s Patented Bio-Pulsed Technology, which enables exosomes to interact with the skin and scalp more effectively.

Real-world Applications

Dr. Wang Si-ching of Nice Clinic shared her team’s clinical experience in utilizing Patented Bio-Pulsed Technology to treat skin aging and presented impressive before-and-after photos. Similarly, Dr. Tsai Zong-hua of Ferrari Clinic, a renowned expert in hair growth, showcased the clinical application of exosomes in hair regeneration, offering hope to individuals suffering from hair loss.

Regulatory Clarity

To ensure the safe and legal use of exosome products, the Taiwan Food and Drug Administration (TFDA) has established specific regulations for exosome cosmetics. During the forum, Yang Zi-yun from the TFDA’s Medical Devices and Cosmetic Division provided a detailed explanation of these regulations, including sales requirements for exosome products and the mandatory individual review process for human exosome raw materials.

Leading the Way in Exosome Innovation

As a pioneer in Induced bio-pulsed exosomes, AM Bio Tech is committed to further advancing research in this field. Beyond medical aesthetics, the company aims to develop innovative exosome-based products for various medical applications, including gynecology, dentistry, ophthalmology, nephrology, orthopedics, otolaryngology, and wound healing. AM Bio Tech is dedicated to bringing these products to the global market, improving the lives of people worldwide.

With outstanding R&D achievements and impressive revenue performance, Ascension Medical Biotechnology (AM BioTech) has formed a partnership with the Medical and Pharmaceutical Industry Technology and Development Center (PITDC) to launch multiple biotech projects and enter the trillion-dollar pharmaceutical market 3

Ascension Medical Biotechnology (AM BioTech), a leading domestic company specializing in exosome functional induction technology and a pioneer in exosome applications for beauty and hair growth, announced on August 30, 2024, its partnership with Medical and Pharmaceutical Industry Technology and Development Center (PITDC) through a “Pharmaceutical Project Cooperation Development Agreement.” This collaboration marks the official launch of several biotech and pharmaceutical development projects, as AM BioTech ventures into the trillion-dollar pharmaceutical market.

Leveraging its exclusive international patent for bio-pulsed technology, AM BioTech has applied this innovation to various medical and cosmetic research areas. The first commercial product utilizing this technology is ExoGiov, the world’s first exosome designed specifically for skin rejuvenation and hair growth. Unlike non-induced exosomes (Naive Exosomes), ExoGiov has achieved international recognition with an INCI certification in 2022. Its remarkable effectiveness, unique market position, and ease of use have led to significant revenue growth. The product, available in lyophilization powder, liquid, and skincare formulations, can be stored at room temperature, reflecting the company’s impressive performance within just three years of its establishment.

Dr. Richard Hsieh, Chairman of AM BioTech, stated that in addition to its applications in beauty and hair growth, the bio-pulsed technology is also being explored for potential pharmaceutical uses in obstetrics and gynecology, dentistry, ophthalmology, nephrology, orthopedics, otolaryngology, and major wound repair. Preclinical efficacy tests have been completed, and most animal trials are finalized, showing promising potential to address unmet medical needs in these fields. The company is actively positioning its international patents and will soon publish four international research papers.

Ensuring legal compliance and product development in both beauty and pharmaceutical sectors remains a core principle for AM BioTech. The company will adhere to international pharmaceutical regulations as it embarks on developing medical projects. The PITDC, renowned for its expertise in pharmaceutical development and regulatory affairs, will collaborate closely with AM BioTech. After extensive discussions and planning between both teams, the agreement will officially commence in September 2024. This partnership signifies a new milestone for AM BioTech as it enters the biotech pharmaceutical development arena.

Ascension Medical Biotechnology (AM BioTech), a leading domestic company specializing in exosome functional induction technology and a pioneer in exosome applications for beauty and hair growth, announced on August 30, 2024, its partnership with Medical and Pharmaceutical Industry Technology and Development Center (PITDC) through a “Pharmaceutical Project Cooperation Development Agreement.” This collaboration marks the official launch of several biotech and pharmaceutical development projects, as AM BioTech ventures into the trillion-dollar pharmaceutical market.

Dr. Mu-Huan Su, Chairman of the PITDC, emphasized that the center’s mission is to assist domestic companies with pharmaceutical product development and guidance while facilitating communication among industry, government, academia, and research sectors. This approach aims to enhance the technical standards of the pharmaceutical industry, promote technological advancement, and achieve industry upgrading and internationalization. The PITDC and AM BioTech have been discussing this project for three years, focusing on pharmaceutical initiatives. Given Taiwan’s relatively small market, it can be challenging for local industries to invest in such R&D. However, AM BioTech’s commitment to substantial research in new indications and applications is highly commendable. This collaboration will not only upgrade but also internationalize Taiwan’s industry. We aim to accelerate AM Biotech’s key pharmaceutical ingredients, product development and launch by partnering with the PITDC research team. Our collaboration will address both domestic and international regulations, enhance quality management systems, and implement manufacturing technologies. This will reduce the risks of AM Biotech’s self-funded development, shorten time to market, and speed up integration into the international supply chain. The planned development will proceed in two stages, aiming to maximize the benefits of domestically produced high-value pharmaceutical products.

Dr. Richard Hsieh, Chairman of AM BioTech, concluded by expressing confidence that, with the combined efforts of both teams, preliminary results will soon be visible, and the commercialization of pharmaceutical products will follow. AM BioTech’s research achievements and patent strategy are well-planned, offering a competitive market advantage. With the PITDC’s support and the collaborative development plan, the launch of AM BioTech’s products in various pharmaceutical applications is anticipated to be imminent.

Read Moreread more

Join Us at Cosmopack Asia 2025

2025-10-23

AM Biotech is honored to participate in Cosmopack Asia 2025, where we will present our

Join Us at the 2025 Autumn International Beauty & Cosmetics Show

2025-09-15

Ascension Medical Biotechnology is dedicated to the research and development of functionally induced exosomes. With

AM Biotech Expands into ASEAN Market at Malaysia-Taiwan Great Health Exhibition Centre

2025-07-18

Taiwan Great Health Exhibition Centre Opens in Kuala Lumpur, Showcasing Healthcare Innovation

Exhibition Dates: July 25 to July 28, 2024
Exhibition Hours: 10:00 AM – 6:00 PM daily (until 5:00 PM on the last day)
Exhibition Venue: Nangang Exhibition Center, Hall 1, 1st Floor, Zone K (No. 1, Jingmao 2nd Road, Nangang District, Taipei City)
Booth Numbers: K622, K624

Biotechnology ✕ Beauty and Health “Asia Healthcare & Medical Cosmetology Expo 2024” showcases projects covering biotech pharmaceuticals, medicine, beauty care, and health. This year, AM Biotech is also participating, presenting our exclusive “Bio-Pulsed” patented technology, scientifically backed beauty and hair care ingredient ExoGiov® Bio-Pulsed Exosomes, and eagerly anticipated new products.

AM Biotech’s Core Technologies

• Exclusive Bio-Pulsed Patent Technology
• Cutting-Edge Manufacturing Process for Mass Production
• Ultra-Purification Extraction Technology for Exosomes
• High-Efficiency Exosome Production Technology for Room Temperature Storage

Advantages of ExoGiov® Bio-Pulsed Exosome Ingredients

• Smooth Wrinkles, Tighten Skin: Promotes the growth of skin-related fibroblasts, anti-inflammation, collagen, and elastin production, with effects 10 to 16 times higher than ordinary exosomes.
• Brighten Skin, Even Out Skin Tone: Degrades melanin miRNA, hundreds of times more effective than ordinary exosomes.
• Strengthen Hair Roots, Revitalize Scalp: Promotes and activates follicle cell growth, with effects 5 to 6 times higher than ordinary exosomes.

Read Moreread more

Join Us at Cosmopack Asia 2025

2025-10-23

AM Biotech is honored to participate in Cosmopack Asia 2025, where we will present our

Join Us at the 2025 Autumn International Beauty & Cosmetics Show

2025-09-15

Ascension Medical Biotechnology is dedicated to the research and development of functionally induced exosomes. With

AM Biotech Expands into ASEAN Market at Malaysia-Taiwan Great Health Exhibition Centre

2025-07-18

Taiwan Great Health Exhibition Centre Opens in Kuala Lumpur, Showcasing Healthcare Innovation

Chronic Kidney Disease (CKD) is increasingly recognized as a significant health concern worldwide. According to a recent report in The Lancet Regional Health, as of 2022, between 9.1% and 13.4% of the global population suffers from CKD.

The kidneys play a critical role in filtering metabolic waste, regulating blood pressure, and maintaining the balance of fluids, electrolytes, and pH in our bodies. However, the onset of chronic illnesses such as diabetes, hypertension, and gout, or the improper use of medication, can lead to CKD. The progression of CKD is slow, often leaving the kidneys in a compromised state for extended periods, which can lead to renal fibrosis—a condition where the kidneys become scarred—and gradually result in a decline in kidney function. Eventually, this may advance to end-stage renal disease (ESRD), at which point most patients require dialysis or a kidney transplant.

A promising avenue for treating CKD, particularly in reducing renal fibrosis, involves the use of engineered extracellular vesicles. These vesicles encapsulate a protein known as CHIP (Carboxyl terminus of Hsp70 Interacting Protein), which plays a crucial role in protein management within cells.

In groundbreaking research highlighted in npj Regenerative Medicine, scientists conducted a study where CHIP-encapsulated extracellular vesicles were administered intravenously to rats that had undergone unilateral ureteral obstruction surgery to induce CKD. This surgery blocks one of the tubes that carries urine from the kidney to the bladder, simulating kidney conditions in humans.

After 14 days of treatment, the rats showed a significant reduction in kidney fibrosis. This result points to a potential non-invasive treatment option that could substantially alter the management of CKD and its progression to more severe stages. This innovative approach not only offers new hope for patients with chronic kidney conditions but also exemplifies the power of advanced biotechnological interventions in regenerative medicine.

Post-UUO Surgery Impact on Renal Fibrosis Treated with Exosomes

For more articlesread more

Emerging Exosome Treatment Shines Hope on Chronic Kidney Disease and Renal Fibrosis

2024-05-24

Chronic Kidney Disease (CKD) is increasingly recognized as a significant health concern worldwide. According to a recent report in The Lancet Regional Health, as of 2022, between 9.1% and 13.4% of the global population suffers from CKD.A promising avenue for treating CKD, particularly in reducing

New Hope for Patients with Hearing Loss: Stem Cell-Derived Exosomes Show Potential for Repairing Cochlear Cells and Nerves

2024-04-24

Risk factors for hearing loss include ear infections, prolonged exposure to high-frequency noise, and unhealthy lifestyle habits, which can cause irreversible damage. In daily life, sounds enter the cochlea as vibrations, where they are transformed into auditory signals by hair cells and then transmitted by

A Breakthrough in Osteoporosis Treatment! Harnessing Exosomes from Skeletal Muscles for Bone Healing

2024-03-27

This groundbreaking study shines a light on the exosomes present in these muscle-secreted humoral factors. This compelling evidence underscores the potential of Myo-EVs in facilitating bone repair and restoring bone health, marking a significant stride in osteoporosis treatment.

Stem Cell Exosomes with Specific miRNAs: A New Frontier in Treating Male Pattern Baldness

2024-03-13

As the exploration of exosomes in clinical settings progresses, there's growing anticipation for their integration with existing treatments like Minoxidil and Finasteride. This innovative approach could herald a more comprehensive and effective solution for tackling male pattern baldness, promising a new era of hair loss

Exosomes Aid in Repairing Skin Aging Caused by UV Radiation

2024-02-02

Overexposure to UV rays stimulates the production of free radicals, leading to wrinkles, spots, and dullness. Therefore, it is essential to use sunscreen and engage in proper skincare to prevent and repair the signs of skin aging.

Anti-Aging Study: Exosomes Regulate Aging Skeletal Muscle

2024-01-05

Extracellular vesicles, including exosomes and microvesicles, are an important medium for intercellular communication, with nearly all cells secreting these vesicles. The research team compared aging muscle stem cells cultured with young serum to those with young serum depleted of extracellular vesicles, observing the impact of

Can Exosomes Also Treat Dry Eye Syndrome?!

2023-12-19

Biologically and medically speaking, immune cells activated after transplantation continuously attack hematopoietic tissues and ocular epithelial tissues, including the cornea, conjunctiva, and lacrimal glands, causing widespread inflammation.